Abstract
Precision medicine promises to transform healthcare for groups and individuals through early disease detection, refining diagnoses and tailoring treatments. Analysis of large-scale genomic–phenotypic databases is a critical enabler of precision medicine. Although Asia is home to 60% of the world’s population, many Asian ancestries are under-represented in existing databases, leading to missed opportunities for new discoveries, particularly for diseases most relevant for these populations. The Singapore National Precision Medicine initiative is a whole-of-government 10-year initiative aiming to generate precision medicine data of up to one million individuals, integrating genomic, lifestyle, health, social and environmental data. Beyond technologies, routine adoption of precision medicine in clinical practice requires social, ethical, legal and regulatory barriers to be addressed. Identifying driver use cases in which precision medicine results in standardized changes to clinical workflows or improvements in population health, coupled with health economic analysis to demonstrate value-based healthcare, is a vital prerequisite for responsible health system adoption.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shapiro, M. D., Tavori, H. & Fazio, S. PCSK9: from basic science discoveries to clinical trials. Circ. Res. 122, 1420–1438 (2018).
Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics—developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014).
Global Spending on Health: a World in Transition (WHO, 2019).
Global Health Estimates 2019: Life Expectancy, 2000–2019 (WHO, 2020).
Schroeder, S. A. Shattuck Lecture. We can do better—improving the health of the American people. N. Engl. J. Med. 357, 1221–1228 (2007).
Roden, D. M. et al. Pharmacogenomics. Lancet 394, 521–532 (2019).
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Olstad, D. L. & McIntyre, L. Reconceptualising precision public health. BMJ Open 9, e030279 (2019).
Middleton, P. G. et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 381, 1809–1819 (2019).
Cully, M. Target validation: genetic information adds supporting weight. Nat. Rev. Drug Discov. 14, 525 (2015).
King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489 (2019).
Ochoa D. et al. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat. Rev. Drug Discov. 21, 551 (2022).
Stark, Z. et al. Integrating genomics into healthcare: a global responsibility. Am. J. Hum. Genet. 104, 13–20 (2019).
The All of Us Research Program Investigators et al. The ‘All of Us’ Research Program. N. Engl. J. Med. 381, 668–676 (2019).
Turnbull, C. et al. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ 361, k1687 (2018).
Stark, Z. et al. Australian genomics: a federated model for integrating genomics into healthcare. Am. J. Hum. Genet. 105, 7–14 (2019).
Cohn, E. G., Henderson, G. E. & Appelbaum, P. S. Distributive justice, diversity, and inclusion in precision medicine: what will success look like? Genet. Med. 19, 157–159 (2017).
Caffrey, M. Disparities in cancer care: has precision medicine widened the gap? AJMC (22 April 2021).
Sirugo, G., Williams, S. M. & Tishkoff, S. A. The missing diversity in human genetic studies. Cell 177, 26–31 (2019).
Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature 590, 290–299 (2021).
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).
Manrai, A. K. et al. Genetic misdiagnoses and the potential for health disparities. N. Engl. J. Med. 375, 655–665 (2016).
Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat. Genet. 51, 584–591 (2019).
Martin, A. R. et al. Human demographic history impacts genetic risk prediction across diverse populations. Am. J. Hum. Genet. 100, 635–649 (2017).
Privé, F. et al. Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. Am. J. Hum. Genet. 109, 12–23 (2022).
Graham, S. E. et al. The power of genetic diversity in genome-wide association studies of lipids. Nature 600, 675–679 (2021).
Atkinson, E. G. et al. Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and to boost power. Nat. Genet. 53, 195–204 (2021).
Mahajan, A. et al. Trans-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat. Genet. 54, 560–572 (2022).
Chambers, J. C. et al. Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case–control study. Lancet Diabetes Endocrinol. 3, 526–534 (2015).
Chandalia, M. et al. Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. PLoS ONE 2, e812 (2007).
Wu, D. et al. Genetic admixture in the culturally unique Peranakan Chinese population in Southeast Asia. Mol. Biol. Evol. 38, 4463–4474 (2021).
Population Trends, 2021 (Singapore Department of Statistics, 2021).
Government Health Expenditure and Healthcare Financing (Singapore Ministry of Health, 2018).
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789–1858 (2018).
Huang, K. K. et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell 33, 137–150 (2018).
Metspalu, A., Köhler, F., Laschinski, G., Ganten, D. & Roots, I. The Estonian Genome Project in the context of European genome research. Dtsch. Med. Wochenschr. 129, S25–S28 (2004).
Chen, J. et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat. Genet. 52, 177–186 (2020).
Bylstra, Y. et al. Implementation of genomics in medical practice to deliver precision medicine for an Asian population. NPJ Genom. Med. 4, 12 (2019).
McGuire, A. L. et al. The road ahead in genetics and genomics. Nat. Rev. Genet. 21, 581–596 (2020).
Life Insurance Association (LIA) Moratorium on Genetic Testing and Insurance (Singapore Ministry of Health, 2021).
Lysaght, T. et al. Trust and trade-offs in sharing data for precision medicine: a national survey of Singapore. J. Pers. Med. 11, 921 (2021).
Lysaght, T. et al. ‘Who is watching the watchdog?’: ethical perspectives of sharing health-related data for precision medicine in Singapore. BMC Med. Ethics 21, 118 (2020).
Ong, S., Ling, J., Ballantyne, A., Lysaght, T. & Xafis, V. Perceptions of ‘precision’ and ‘personalised’ medicine in Singapore and associated ethical issues. Asian Bioeth. Rev. 13, 179–194 (2021).
Majithia, S. et al. Cohort profile: the Singapore Epidemiology of Eye Diseases study (SEED). Int. J. Epidemiol. 50, 41–52 (2021).
Tan, K. et al. Cohort profile: the Singapore Multi-Ethnic Cohort (MEC) study. Int. J. Epidemiol. 47, 699–699j (2018).
Soh, S. et al. Cohort profile: Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth cohort study. Int. J. Epidemiol. 43, 1401–1409 (2014).
Yap, J. et al. Harnessing technology and molecular analysis to understand the development of cardiovascular diseases in Asia: a prospective cohort study (SingHEART). BMC Cardiovasc. Disord. 19, 259 (2019).
Van der Auwera G. A. & O'Connor, B. D. Genomics in the Cloud: Using Docker, GATK, and WDL in Terra 1st edn (O’Reilly Media, 2020).
Poplin, R. et al. Scaling accurate genetic variant discovery to tens of thousands of samples. Preprint at bioRxiv https://doi.org/10.1101/201178 (2018).
McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
Code of Practice for Key Office Holders Under the Healthcare Services Act (Singapore Ministry of Health, 2019).
Doyle, D. L. et al. 2013 review and update of the genetic counseling practice based competencies by a task force of the accreditation council for genetic counseling. J. Genet. Couns. 25, 868–879 (2016).
Christenhusz, G. M., Devriendt, K. & Dierickx, K. To tell or not to tell? A systematic review of ethical reflections on incidental findings arising in genetics contexts. Eur. J. Hum. Genet. 21, 248–255 (2013).
Green, R. C. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15, 565–574 (2013).
eMERGE Clinical Annotation Working Group. Frequency of genomic secondary findings among 21,915 eMERGE network participants. Genet. Med. 22, 1470–1477 (2020).
Kuo, C. W. et al. Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes. Mol. Genet. Genomic Med. 8, e1455 (2020).
Chen, W. et al. Secondary findings in 421 whole exome-sequenced Chinese children. Hum. Genomics 12, 42 (2018).
Van Hout, C. V. et al. Exome sequencing and characterization of 49,960 individuals in the UK Biobank. Nature 586, 749–756 (2020).
Cohen, J. T., Goodell, S. & Neumann, P. J. The cost savings and cost-effectiveness of clinical preventive care. In Synthesis Project (Robert Wood Johnson Foundation, 2009).
Hatz, M. H., Schremser, K. & Rogowski, W. H. Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics 32, 443–455 (2014).
Kasztura, M., Richard, A., Bempong, N. E., Loncar, D. & Flahault, A. Cost-effectiveness of precision medicine: a scoping review. Int. J. Public Health 64, 1261–1271 (2019).
Acknowledgements
We thank all investigators, staff members and study participants of the contributing cohorts and studies: (1) the HELIOS study at the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; (2) the GUSTO study jointly hosted by the National University Hospital, KK Women’s and Children’s Hospital, the National University of Singapore and the Singapore Institute for Clinical Sciences, the Agency for Science Technology and Research (A*STAR); (3) the SEED cohort at the Singapore Eye Research Institute; (4) the MEC, National University of Singapore; (5) the PRISM cohort; and (6) the TTSH Personalised Medicine Normal Controls cohort. We also thank the National Supercomputing Centre, Singapore (https://www.ncss.sg) for computation resources. The SG10K_Health project is funded by the Industry Alignment Fund (Pre-Positioning) (IAF-PP, H17/01/a0/007); the project made use of participating study cohorts supported by the following funding sources: (1) the HELIOS study by grants from a Strategic Initiative at Lee Kong Chian School of Medicine, the Singapore MOH under its Singapore Translational Research Investigator Award (NMRC/STaR/0028/2017) and the IAF-PP (H18/01/a0/016); (2) the GUSTO study by the Singapore National Research Foundation under its Translational and Clinical Research Flagship Program and administered by the Singapore MOH’s National Medical Research Council Singapore (NMRC/TCR/004-NUS/2008, NMRC/TCR/012-NUHS/2014) with additional funding support available through the A*STAR and the IAF-PP (H17/01/a0/005); (3) the SEED study by NMRC/CIRG/1417/2015, NMRC/CIRG/1488/2018 and NMRC/OFLCG/004/2018; (4) the MEC by individual research and clinical scientist award schemes from the Singapore National Medical Research Council (including MOH-000271-00) and the Singapore Biomedical Research Council, the Singapore MOH, the National University of Singapore and the Singapore National University Health System; (5) the PRISM cohort study by NMRC/CG/M006/2017_NHCS, NMRC/STaR/0011/2012, NMRC/STaR/0026/2015, the Lee Foundation and the Tanoto Foundation; and (6) the TTSH cohort study by NMRC/CG12AUG2017 and CGAug16M012. This research is also supported by the National Research Foundation Singapore under its NPM program Phase II funding (MOH-000588) and administered by the Singapore MOH’s National Medical Research Council.
Author information
Authors and Affiliations
Consortia
Contributions
Conceived and led the NPM program: P.T., E.S.T. and J.C.C. Cohort recruitment and sample collection: J.Lee, J.J.Y.S., T.Y.W., C.W.L.C., P.D.G., L.L.G., X.S., C.Y.Cheng, S.D., N.K., K.P.L., E.S.T. and J.C.C. Sample processing and data analysis: N.B., M.H., R.T.M., C.B., W.K.L., J.F.C., J.Liu, S.P., S.M.S., C.S.V., P.K. and R.S.M.G. Enabling Platform workgroup: P.T., C.Y.Chua, K.H.K.B. and T.W.T. Regulation and Ethics workgroup: P.M.L.T. and R.C. Clinical Adoption workgroup: K.M., I.C., D.L., S.V. and M.K. Public and Community Trust workgroup: T.M.L., C.H. and S.W.S. Industry Development workgroup: W.Y.C., K.E.T., J.Y., W.Z. and Y.K.S. Workforce Development workgroup: K.T.G. The SG10K_Health Consortium was involved in sample collection and processing and data analysis. The manuscript was co-written by E.W., P.T., E.S.T. and J.C.C.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Genetics thanks Mark Caulfield and Philip Wilcox for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wong, E., Bertin, N., Hebrard, M. et al. The Singapore National Precision Medicine Strategy. Nat Genet 55, 178–186 (2023). https://doi.org/10.1038/s41588-022-01274-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-022-01274-x
